# 1. Financial Performance ## A. Key Figures * **Standalone Net Revenue:** **₹3,838 Mn** (Q1 FY26) (+12.5% QoQ, -2.6% YoY) · **Consolidated Net Revenue:** **₹4,291 Mn** (Q1 FY26) (+11.8% QoQ, +1.1% YoY) * **Net Debt:** **₹951 Cr** (as of 30-Jun) (-₹21 Cr QoQ) · **Total Debt:** **₹950 Cr** (₹350 Cr ST + ₹600 Cr LT) * R&D Expenses: ₹21.6 Cr (Q1 FY26) · Other Expenses: ₹157 Cr (Q1 FY26) ## B. Revenue Growth * **Divergent Standalone Trends:** Standalone revenue shows sequential improvement but remains materially below prior-year levels, indicating partial recovery. * **Consolidated Rebound:** Consolidated revenue grew both sequentially and year-over-year, reflecting stronger performance at the group level. ## C. EBITDA Margins * **Standalone Margin Surge:** Standalone EBITDA margin expanded sharply, signaling strong operational leverage or cost control. * **Consolidated Recovery from Negative Base:** Consolidated margin turned positive after a loss-making prior quarter, though still below year-ago levels. ## D. Net Debt & Debt Repayment * **Debt Reduction Underway:** Net debt reduced by ₹21 Cr in Q1, with a further **₹68 Cr repayment** scheduled within the next nine months. * **Debt Structure Stable:** Long-term debt dominates the capital structure, with no major refinancing risk flagged. ## E. R&D and Other Expenses * **R&D Focus on Complex Generics:** R&D spend elevated in Q1 due to upfront project costs; full-year R&D expected at **5%–5% of revenue**, targeting 4–5 filings. * **Other Expenses Moderating:** Despite inflationary pressures, other expenses declined slightly from peak levels and are expected to grow slower than revenue. * **Cost Control Initiatives:** Solar adoption and tighter monitoring of **advertising, travel, and power** aim to improve cost efficiency. * **One-Offs Embedded:** Current expense levels include **remediation and one-time costs**; underlying run rate targeted at **₹140 Cr** consolidated. --- # 2. Product & Segment Performance ## A. Key Figures * OTC Revenue: ₹31.6 Cr Q1 FY25–26 (vs. prior quarter +46%) * API Revenue: ₹366 Mn (up from ₹312 Mn) · ₹50 Mn from AnaCipher CRO & Indoco Analytical (down from ₹57 Mn) * **Domestic Formulation Revenue:** **₹2,028 Mn** Q1 FY25–26 (+1.3% YoY from ₹2,002 Mn) * **API Sales Breakdown:** **₹16 Cr** domestic (export-focused) · **₹21 Cr** exports outside continent ## B. OTC Business Growth * **Robust Momentum:** OTC business delivered strong sequential growth, supported by double-digit expansion across all top four therapeutic segments. * **Productivity Initiative:** Management targeting significant uplift in field force productivity by lifting low-performing **PHY per rep to minimum 2**, with goal of adding **25,000+ incremental PHY** by year-end. * **Marketing Leverage:** Lower-than-budgeted marketing spend in Q1 boosted profitability, despite ongoing high investments in digital and direct-to-consumer channels. ## C. API Sales Mix * **Export-Dominated API Growth:** API revenue surge driven by strong export demand, with nearly all sales comprising **DMS-grade, export-formulation materials** at uniform pricing. * **CRO/Analytical Softness:** Revenue decline in contract research and analytical services indicates near-term weakness in non-core API segments. ## D. Formulation Revenues * **Domestic Formulation Recovery:** Significant YoY rebound in domestic formulations, led by strong performance in GI, Anti-infectives, Stomatology, and Respiratory segments. * **Mixed Field Productivity:** MR productivity averages **3+**, with acute care divisions reaching **5–4**, while niche segments like Ophthal lag below **2** due to portfolio realignment. --- # 3. Manufacturing & Approvals ## A. Key Figures * **International Business Growth:** **26%** increase driven by Phase-1 rollout * **Net Worth Status:** **₹52 Cr** negative net worth for Warren Remedies; capital infusion planned over next 3 quarters * **US FDA Line Restart:** **Go-ahead received by end-May**; supply impact expected in **Q3** ## B. Plant-2 Progress * **Full Operational Timeline:** All plants on track to be fully operational by start of Q3 following completion of rollout by end of Q ## C. Sterile Product Approvals * **European Market Access Achieved:** Goa Plant-2 received GMP certification from European authorities, enabling sale of key sterile products and paving way for additional filings. * **Regulatory Progress with Disclosure Constraints:** Sterile product approvals advancing in Europe, though timelines remain undisclosed due to fragmented country-level regulations. ## D. Phase-1 Rollout Impact * **Phase-1 Driving Export Growth:** Solid oral exports boosted by successful Phase-1 implementation across 3 of 4 planned plants, contributing to strong international performance. * **Path to Full Efficiency:** Current manufacturing underway but optimal efficiency awaits balanced product mix and stable order flow, with improvements anticipated in Phase-2. ## E. US FDA Line Restart * **Restart Underway, Sales Imminent:** Two US FDA-cleared lines restarted after May-end approval; newly manufactured complex ophthalmic products (e.g., Brinzolamide, Combigan) expected to enter supply chain in Q3. * **Final Line Targeted for Calendar Year Completion:** Remaining line restart anticipated within current calendar year, though no formal inspection or approval date set. --- # 4. Geography & Market Mix ## A. Key Figures * International Formulation Revenue: ₹1,393M (current quarter) vs ₹1,571M (prior year) * Europe Revenue: ₹63.5 Cr (current quarter) * Regulated Markets Revenue: ₹950 Mn vs. ₹1,273 Mn (same quarter last year) * US Business Revenue: ₹283 Mn vs. ₹487 Mn (prior year) * Semi-Regulated Markets Revenue (SA, AU, NZ): ₹32 Mn (flat YoY) * Emerging Markets Revenue: ₹443 Mn vs. ₹298 Mn (prior year) ## B. Europe Supply Update * **Supply Disruptions Contained:** Europe revenues reflect ongoing supply constraints, with **normal supply expected to resume by Q3** following resolution of issues by end-Q2. ## C. US Market Outlook * **Regulated Markets Surge Amid US Slowdown:** Strong overall regulated revenue growth driven by non-US segments, while US revenues declined due to **uncertain FDA inspection timeline**, delaying visibility on revenue ramp-up into **Q3–Q1 next fiscal**. ## D. Semi-Regulated Growth * **Sustained Momentum in Semi-Regulated Markets:** Robust expansion across **Africa, LATAM, and Asia**, fueled by India-style branding, sales restructuring in **French West Africa**, and corporate support; management expects current growth trajectory to continue. ## E. Domestic IRL Performance * **Domestic Growth Outpaces Industry:** IRL business grew **10% YoY per IQVIA**, above the 8% market average, with **5% overall growth including Warren OTC** despite flat core performance. * **Seasonal Headwinds Impact Primary Sales:** Climate-related disruptions caused **unusual simultaneous declines in Cital and Cyclopam at primary level**, though **Cyclopam gained share (secondary sales +4%)** in a sub-6% market. --- # 5. Regulatory & Compliance Risks ## A. Key Figures * **Remediation Cost:** **₹4 Cr** per quarter (ongoing) ## B. FDA Warning Letter * **Partial Manufacturing Resumed:** FDA has allowed operations on **2 of 4 lines** at Goa Plant-2 amid ongoing remediation. * **Remediation Nearing Completion:** Majority of corrective actions expected to be completed by **August**, with final updates through December; **FDA audit to be requested from September**. * **Cost Pressure Persists:** Remediation continues to incur **steady quarterly costs of ₹4 Cr**, with no near-term relief anticipated. ## C. Remediation Timeline * **Inspection Expected Pre-December:** Regulatory review of Plant-2 anticipated before year-end, a key step toward lifting the warning letter and **resuming US supply**. ## D. GMP Certification Status * **European Approval Secured:** GMP certification achieved for EU market access, unlocking a **₹65 Cr opportunity**, though scaling strategy remains undefined. --- # 6. Guidance & Outlook ## A. Key Figures * **CAPEX FY '26:** **₹50 Cr** incremental spend (no major expansion) ## B. CAPEX Plan * **Disciplined Investment:** Incremental CAPEX limited to ₹50 Cr, focused on completion of ongoing projects at **Goa Plant-2** and **API site for Warren Remedies**; no new greenfield or maintenance-driven outlays planned. ## C. EBITDA Target * **Margin Recovery Goal:** Management targeting restoration of **EBITDA margins to 11%–13% range**, reversing recent declines through CAPEX discipline and operational efficiency initiatives. ## D. Breakeven Forecast * **Warren Remedies Inflection:** Achieved **EBITDA breakeven in Q1**, with expectation to sustain performance and remain breakeven at EBITDA level over the next few years. * **Near-Term Cautiousness:** Despite H2/FY '25 headwinds and negative mark-to-market impact, Q1 FY '26 shows marginal improvement; management refrains from long-term guidance, prioritizing cost containment across manufacturing and sales.